- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02929303
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
February 15, 2019 updated by: Hector Hernandez
Expanded Access of Omegaven IV Fat Emulsion (Fish Oil Infusion) to Infants and Children With Parenteral Nutrition-associated Liver Disease
This is an expanded access protocol for use of intravenous fish oil infusion, Omegaven, in infants and children with parenteral nutrition associated liver disease (PNALD) to decrease elevated liver enzymes and direct bilirubin.
This study aims to describe the response of PNALD after use of Omegaven by normalization of serum levels of liver enzymes and bilirubin.
Study Overview
Status
Approved for marketing
Intervention / Treatment
Detailed Description
The etiology of parenteral nutrition associated liver disease (PNALD) is currently considered multifactorial.
Available treatment options for this disease process are limited and have achieved moderate success at best.
Unlike conventional intravenous fat emulsions, Omegaven™ is comprised solely of fish oils containing primarily omega-3 fatty acids.
The investigators hypothesize that administering Omegaven™ to patients with PNALD in place of conventional fat emulsion may reverse cholestasis allowing patients to be maintained on adequate PN until they are able to ingest adequate nutrition enterally.
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Advocate Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pediatric patients aged 0 - 18 yrs
- Patients will be PN dependent (unable to meet nutritional needs solely by enteral nutrition). It will be assumed that patients will require parenteral nutrition for at least 30 days from the inclusion into the study.
- Patients must have parenteral nutrition associated liver disease (PNALD) as defined as a direct bilirubin of 2mg/dl or more. Other causes of liver disease should be excluded. A liver biopsy is not necessary for treatment.
- 2 consecutive direct bilirubins > 2.0 mg/dl. one week apart.
- Signed patient informed consent.
- The patient must have utilized standard therapies as clinically appropriate to prevent the progression of his/her liver disease. Such therapies could include surgical treatment, cyclic PN, avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding, and the use of ursodiol (i.e.,Actigall).
Exclusion Criteria:
- Documented cause of chronic liver disease other than parenteral nutrition associated liver disease.
- An allergy to any seafood product, egg protein, and/or previous allergy to Omegaven.
- Active coagulopathy characterized by ongoing bleeding or by a requirement for clotting factor replacement (e.g. fresh frozen plasma or cryoprecipitate) to maintain homeostasis.
- Impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis.(e.g. (triglycerides > 1000mg/dl while receiving intralipid 1g/kg/day or less)
- Unstable diabetes mellitus or hyperglycemia (Blood glucose >200 mg/dL) at the time of initiation of Omegaven
- Currently being treated for stroke, embolism, collapse and shock, myocardial infarction.
- Cholestasis due to any reason other than parenteral associated liver disease
- Active new infection at time of initiation of Omegaven
- Hemodynamic instability (e.g. receiving vasopressors) at time of initiation of Omegaven.
- The patient may not be enrolled in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team).
- Known pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sant'Anna AM, Altamimi E, Clause RF, Saab J, Mileski H, Cameron B, Fitzgerald P, Sant'Anna GM. Implementation of a multidisciplinary team approach and fish oil emulsion administration in the management of infants with short bowel syndrome and parenteral nutrition-associated liver disease. Can J Gastroenterol. 2012 May;26(5):277-80. doi: 10.1155/2012/571829.
- Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr. 2010 Feb;156(2):327-31. doi: 10.1016/j.jpeds.2009.08.033.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 13, 2016
First Submitted That Met QC Criteria
October 7, 2016
First Posted (Estimate)
October 11, 2016
Study Record Updates
Last Update Posted (Actual)
February 19, 2019
Last Update Submitted That Met QC Criteria
February 15, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K5900315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Total Parenteral Nutrition-induced Cholestasis
-
Cindy HallerTerminatedCholestasis | Total Parenteral Nutrition-induced CholestasisUnited States
-
Jeffrey RudolphUniversity of PittsburghApproved for marketingTotal Parenteral Nutrition-induced CholestasisUnited States
-
PediatrixCompletedTotal Parenteral Nutrition-induced CholestasisUnited States
-
Rush University Medical CenterApproved for marketingCholestasis | Total Parenteral Nutrition-induced CholestasisUnited States
-
Sivan KinbergWithdrawnTotal Parenteral Nutrition-induced CholestasisUnited States
-
Johane AllardUniversity of Alberta; Hamilton Health Sciences Corporation; St. Paul's Hospital... and other collaboratorsTerminatedTotal Parenteral Nutrition-induced CholestasisCanada
-
Wake Forest University Health SciencesCompletedTotal Parenteral Nutrition-induced CholestasisUnited States
-
University of NebraskaChildren's Hospital and Medical Center, Omaha, NebraskaApproved for marketingTotal Parenteral Nutrition-Induced CholestasisUnited States
-
Mayyada Elsayed Mohamed HussienNot yet recruitingNeonatal Cholestasis | Total Parenteral Nutrition Effect
-
Institute of Child HealthCompletedSurgical Infants Requiring Total Parenteral NutritionUnited Kingdom
Clinical Trials on Omegaven IV lipid emulsion
-
Children's Mercy Hospital Kansas CityCompletedParenteral Nutrition-related HepatitisUnited States
-
Wake Forest University Health SciencesCompletedTotal Parenteral Nutrition-induced CholestasisUnited States
-
Northwell HealthNo longer available
-
Sivan KinbergWithdrawnTotal Parenteral Nutrition-induced CholestasisUnited States
-
Radboud University Medical CenterCompleted
-
Kapiolani Medical Center For Women & ChildrenCompleted
-
Alexandra N. CareyCompletedHematopoietic Stem Cell TransplantationUnited States
-
Fresenius KabiNot yet recruitingMalnutrition | Pediatric ALL | Essential Fatty Acid Deficiency | Parenteral Nutrition Associated Liver Disease (PNALD)
-
Fresenius KabiWithdrawnMalnutrition | Pediatric ALL | Neurocognitive Deficit | Parenteral Nutrition Associated Liver Disease | Essential Fatty Acid Deficiency
-
University of OklahomaOU Medical CenterCompletedInfant, Premature, Diseases | Cholestasis | Gastroschisis | Intestinal Atresia | Short Bowel Syndrome | Cholestasis of Parenteral Nutrition | Total Parenteral Nutrition-induced CholestasisUnited States